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Mycobacterium tuberculosis (Mtb) requires an alternative protein secretion system, ESX1, for virulence.
Recently, Raghavan et al. (2008) reported a new regulatory circuit that may explain how ESX1 activity is
controlled during infection. Mtb appears to regulate ESX1 by modulating transcription of associated genes
rather than structural components of the secretion system itself.All bacterial pathogens face similar chal-
lenges within the infected host. They
must survive the onslaught of innate and
adaptive immunity, acquire nutrients,mul-
tiply, and be transmitted. In a diverse mi-
crobial universe, such similar problems
might be solved in very different ways.
Yet many pathogens seem to have con-
verged on a few solutions. For example,
many bacterial pathogens use specialized
secretion systems to translocate effector
molecules into their host cells in order to
manipulate host cell targets. The type III
and type IV secretion systems are found
in a variety of gram-negative pathogens
and are required for the virulence of these
organisms. In both systems, bacteria se-
crete and assemble components of a
complex extracellular machine. They
then use these machines to inject, in nee-
dle-like fashion, effectors across host cell
membranes into privileged host cell com-
partments.
Mycobacterium tuberculosis, which
causes the clinical disease tuberculosis,
is an intracellular pathogen of macro-
phages and like other intracellular patho-
gens,Mtbmodulates many host cell func-
tions to its own advantage. Because Mtb
alters various macrophage processes
while growing within a phagolysosomal
vacuole, it seems reasonable to expect
thatMtbmight contain a functional ortho-
log of the type III and type IV secretion
systems. While no such system has
been identified, there is a contender. The
ESX1 secretion system is an alternative
protein secretion system that is required
for Mtb to survive and grow in macro-
phages and animals. The biologic impor-
tance of ESX1 is highlighted by the find-
ing that the primary attenuating deletion
in BCG, the vaccine strain of Mtb, is the190 Cell Host & Microbe 4, September 11, 2loss of nine genes from the heart of the
ESX1 locus (Lewis et al., 2003; Mahairas
et al., 1996). While obviously of biologic
importance, the molecular details of
ESX1 function are not clear and major
questions remain. Do ESX1 components
assemble into a needle-like translocon?
Does the system secrete effector mole-
cules into the host cell and if so, what
are these effectors and what are their tar-
gets? Or are we imposing an appealing
model on a system that functions in a fun-
damentally different way?
Indeed ESX1 differs in some ways from
the better-studied type III and IV secretion
systems. ESX1 is only one of five homolo-
gous ESX secretion systems in the Mtb
genome (Gey Van Pittius et al., 2001).
Like the other ESX genes, genes in the
ESX1 locus are constitutively expressed
under all studied growth conditions, and
there is no evidence that ESX1 expression
is induced in vivo (Schnappinger et al.,
2003; Talaat et al., 2007). Furthermore, it
is striking that ESX1 seems constitutively
active under in vitro conditions, whereas
effectors of the type III and type IV sys-
temsare produced and secreted in a care-
fully orchestratedmanner specifically dur-
ing infection. These observations raise the
possibility that since Mtb is an obligate
human pathogen, it may not have ac-
quired a pathway to switch on and off its
virulence systems.
However, this month in Nature, Ragha-
van and colleagues identify an intriguing
newpathway that at leastpartially explains
how ESX1 activity might be regulated dur-
ing infection (Raghavan et al., 2008).
The key to this regulatory circuit is
a novel transcription factor, EspR, which
positively regulates the expression of a
five gene operon, Rv3616c-3612c, which008 ª2008 Elsevier Inc.is unlinked to the ESX1 locus. Two genes
in the locus, Rv3615c andRv3614c, are in-
dependently required for ESX1-mediated
secretion (MacGurn et al., 2005). One of
the gene products, Rv3616c (also known
as EspA), is one of the four known sub-
strates of the apparatus. Since all four of
these proteins are secreted in a codepen-
dent fashion (Fortune et al., 2005), titration
of the Rv3616c-14c operon is sufficient to
regulate ESX1 activity—at least as we
understand it. These observations com-
plement recent data showing that a two-
component regulatory system, PhoP/R,
also regulatesESX1 functionbycontrolling
the expression of genes in the Rv3616-
Rv3612c locus (Frigui et al., 2008).
Thus, M. tuberculosis appears to regu-
late the function of ESX1 by modulating
Rv3616c-3612c transcription instead of
the structural components of the secre-
tion system itself. Perhaps regulation of
this relatively small number of ESX1-asso-
ciated proteins allows dynamic regulation
of ESX1 activity without requiring the bac-
terium to rapidly assemble and disassem-
ble the core secretion machine, which
could be a relatively difficult and costly
undertaking given the complexity of the
mycobacterial cell wall. It is also possible,
however, that Rv3616c-Rv3612c serves
a more specific virulence function than
the ESX1 secretion system as a whole.
In Mycobacterium marinum, a water-
borne pathogenic mycobacterium whose
natural hosts range from amoebae to
frogs and fish, there has been a dramatic
reduplication of Rv3616c homologs with-
out expansion of any of the other ESX1
genes, raising the possibility that the eigh-
teen homologs of Rv3616c provide host,
tissue, or milieu specificity to ESX1 secre-
tion (Stinear et al., 2008).
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that the regulation of Rv3616c-Rv3612c
expression is directly linked to ESX1 func-
tion in an unusual way. Not only is EspR
a DNA-binding protein that positively reg-
ulates Rv3616c-Rv3612c transcription,
but it is also a substrate of the ESX1
apparatus. Thus, when ESX1 is active, it
secretes EspR and shuts itself down. It
is notable that other bacteria use a similar
strategy to regulate alternative secretion
systems. In both flagellar assembly and
the evolutionarily related type III secretion
system of Pseudomonas, the apparatus
secretes negative regulators of substrate
expression allowing the bacteria to rapidly
increase the amount of substrate when
secretion is triggered (Brutinel and
Yahr, 2008).
Some observations suggest that inMtb
this regulatory loop is likely to be more
complex and involve other proteins and
interactions. First, deletion of the core
secretion apparatus, which should lead
to cytosolic accumulation of EspR and
concomitant transcriptional changes, has
been shown to have a minimal effect on
gene expression. Second, in contrast to
the regulatory loops associated with type
III secretion and flagellar assembly, Mtb
secretes a positive transcriptional reg-
ulator. This creates a negative feedback
loop in which a burst of ESX1 secretion is
presumably followed by ESX1 inactiva-
tion. The predicted pattern of oscillating
secretion is somewhat at odds with the
observation that ESX1 is constitutively ac-
tive, at least in vitro. There are a couple ofpossible explanations. First, the discrep-
ancy may come from studying a popula-
tion of bacteria where secretion in each
individual bacterium is oscillating in an un-
synchronized fashion. Alternatively, other
factors in vivomay affect EspRexpression
such that after a period of ESX1 activity,
secretion is permanently turned off.
And why might the bacteria turn off
ESX1 secretion during infection, espe-
cially when ESX1 seems required for bac-
teria to survive in macrophages? Raga-
havan et al. point out that many ESX1
substrates are strong T cell antigens and
that downregulation of ESX1-mediated
secretion may allow the bacteria to be-
come antigenically silent (Raghavan
et al., 2008). If so, this could explain why
some bacteria survive in the face of an ap-
parently robust antigen-specific immune
response. Alternatively, ESX1-mediated
secretion might be important at certain
times during infection (e.g., for survival in
the phagolysosome) but deleterious at
other times (e.g., growth in caseum). This
again would suggest that individual cells
might be turning secretion on and off
even when population analysis suggests
that expression is ongoing. In either
case, single-cell studiesmight be required
to establish the conditions of regulation.
The big question remains—what is the
function of ESX1? While studies such as
this do not elucidate the reason that
ESX1 is required for virulence, they can
help to determine the circumstances un-
der which these proteins are required.
Thus, while we do not yet know the an-Cell Host & Microbe 4,swer, we can begin to establish guilt by
association.
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